Physician profile
Kelsey E Grimmer
NPI 1265695530
$8,487.85
in general payments reported to CMS, 2019-2025
28 companies · $1,655 in 2025
The $1,655 reported for 2025 was more than what 88% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $768 · 2022: $1,183 · 2023: $2,560 · 2024: $2,323 · 2025: $1,655.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,262 · Education: $275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,262.44 |
| Education | $274.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,276.54 | 2021-2025 | |
| Janssen Biotech, INC. | $1,104.95 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Genzyme Corporation | $1,055.03 | 2021-2025 | |
| Lilly USA, LLC | $960.26 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $585.04 | 2021-2025 | Dupixent |
| Amgen INC. | $484.97 | 2021-2024 | Otezla |
| Sun Pharmaceutical Industries INC. | $416.48 | 2021-2025 | Winlevi, Ilumya, Absorica Ld |
| Incyte Corporation | $382.84 | 2022-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $316.61 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $281.00 | 2022-2025 | Sotyktu |
| Ucb, INC. | $270.29 | 2024-2025 | Bimzelx |
| Dermavant Sciences, INC. | $259.00 | 2023-2024 | Vtama |
| Mayne Pharma Commercial LLC | $208.79 | 2022-2025 | |
| Galderma Laboratories, L.P. | $180.23 | 2021-2025 | Aklief, Nemluvio, Epsolay |
| Arcutis Biotherapeutics, INC. | $112.14 | 2023-2025 | Zoryve |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epi Health, LLC | $104.79 | 2021-2022 | |
| Leo Pharma INC. | $93.28 | 2022-2025 | Adbry |
| Organon LLC | $72.09 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $63.40 | 2024 | Cabtreo, Jublia |
| Almirall LLC | $46.98 | 2021-2022 | |
| Journey Medical Corporation | $39.98 | 2023-2025 | |
| Pfizer INC. | $35.80 | 2024-2025 | |
| Genentech USA, INC. | $31.48 | 2022 | |
| Strata Skin Sciences, INC. | $25.15 | 2024 | Xtrac |
| Verrica Pharmaceuticals INC. | $22.85 | 2024 | Ycanth |
| Botanix Sb INC | $21.37 | 2025 | Sofdra |
| Lnhc, INC | $19.02 | 2025 | Zelsuvmi |
| Biofrontera INC. | $17.49 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelsey Grimmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.